BSE Live
Jan 09, 16:01Prev. Close
22.63
Open Price
22.01
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Beryl Drugs (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 1.14 | 1.52 | 1.52 | -1.30 | 0.47 | |
| Diluted EPS (Rs.) | 1.14 | 1.52 | 1.52 | -1.30 | 0.47 | |
| Cash EPS (Rs.) | 3.58 | 3.87 | 3.10 | 0.84 | 2.97 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 18.66 | 17.52 | 15.84 | 14.32 | 15.57 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 18.66 | 17.52 | 15.84 | 14.32 | 15.57 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 41.51 | 52.48 | 52.79 | 28.67 | 27.67 | |
| PBDIT/Share (Rs.) | 5.18 | 5.25 | 4.35 | 1.12 | 3.21 | |
| PBIT/Share (Rs.) | 2.74 | 2.89 | 2.75 | -1.01 | 0.71 | |
| PBT/Share (Rs.) | 1.70 | 1.98 | 1.93 | -1.87 | 0.68 | |
| Net Profit/Share (Rs.) | 1.14 | 1.51 | 1.50 | -1.29 | 0.47 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 12.48 | 10.00 | 8.23 | 3.92 | 11.60 | |
| PBIT Margin (%) | 6.59 | 5.51 | 5.20 | -3.51 | 2.56 | |
| PBT Margin (%) | 4.09 | 3.77 | 3.65 | -6.50 | 2.46 | |
| Net Profit Margin (%) | 2.73 | 2.87 | 2.84 | -4.51 | 1.70 | |
| Return on Networth / Equity (%) | 6.09 | 8.61 | 9.49 | -9.03 | 3.02 | |
| Return on Capital Employed (%) | 11.96 | 12.55 | 12.51 | -5.50 | 3.46 | |
| Return on Assets (%) | 3.62 | 4.39 | 4.37 | -3.69 | 1.28 | |
| Total Debt/Equity (X) | 0.43 | 0.57 | 0.56 | 0.73 | 0.55 | |
| Asset Turnover Ratio (%) | 1.26 | 1.53 | 1.52 | 0.80 | 75.57 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.10 | 1.78 | 1.63 | 1.25 | 1.24 | |
| Quick Ratio (X) | 1.66 | 1.56 | 1.46 | 0.90 | 0.96 | |
| Inventory Turnover Ratio (X) | 13.37 | 11.50 | 7.06 | 3.32 | 6.21 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 13.98 | 19.81 | 10.16 | 10.35 | 7.25 | |
| EV/Net Operating Revenue (X) | 0.66 | 0.74 | 0.38 | 0.71 | 0.51 | |
| EV/EBITDA (X) | 5.29 | 7.41 | 4.59 | 18.06 | 4.44 | |
| MarketCap/Net Operating Revenue (X) | 0.51 | 0.56 | 0.23 | 0.36 | 0.24 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 1.13 | 1.67 | 0.77 | 0.73 | 0.42 | |
| Price/Net Operating Revenue | 0.51 | 0.56 | 0.23 | 0.36 | 0.24 | |
| Earnings Yield | 0.05 | 0.05 | 0.12 | -0.12 | 0.07 |
14.11.2025
Beryl Drugs Standalone September 2025 Net Sales at Rs 5.12 crore, down 8.8% Y-o-Y
22.08.2025
Beryl Drugs Standalone June 2025 Net Sales at Rs 4.79 crore, down 23.28% Y-o-Y
12.06.2025
Beryl Drugs Standalone March 2025 Net Sales at Rs 3.97 crore, up 33.54% Y-o-Y
14.02.2025
Beryl Drugs Standalone December 2024 Net Sales at Rs 5.31 crore, down 30.35% Y-o-Y
14.11.2025
Beryl Drugs Standalone September 2025 Net Sales at Rs 5.12 crore, down 8.8% Y-o-Y
22.08.2025
Beryl Drugs Standalone June 2025 Net Sales at Rs 4.79 crore, down 23.28% Y-o-Y
12.06.2025
Beryl Drugs Standalone March 2025 Net Sales at Rs 3.97 crore, up 33.54% Y-o-Y
14.02.2025
Beryl Drugs Standalone December 2024 Net Sales at Rs 5.31 crore, down 30.35% Y-o-Y